WILMINGTON, Del. • British drugmaker AstraZeneca PLC is eliminating 1,600 jobs, mostly in the U.S. and United Kingdom, under a global restructuring meant to reduce costs and make research programs more productive.
The cuts amount to nearly 3 percent of AstraZeneca's 57,200 workers around the world. The world's fifth-largest drugmaker by revenue also will move its global headquarters from London to Cambridge, England, by 2016.
In the U.S., AstraZeneca will scale back its site in Wilmington, Del., eliminating about 650 jobs and shifting 550 more to other company locations.